These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11601672)

  • 1. The "superiority" of enoxaparin for treatment of acute coronary syndromes.
    Noviasky JA; Gaffney BJ
    Pharmacotherapy; 2001 Oct; 21(10):1250-2. PubMed ID: 11601672
    [No Abstract]   [Full Text] [Related]  

  • 2. A contemporary assessment of low-molecular-weight heparin for the treatment of acute coronary syndromes: factoring in new trials and meta-analysis data.
    Topol EJ
    Am Heart J; 2005 Apr; 149(4 Suppl):S100-6. PubMed ID: 16124950
    [No Abstract]   [Full Text] [Related]  

  • 3. Pursuing progress in acute coronary syndromes.
    Armstrong PW
    Circulation; 1999 Oct; 100(15):1586-9. PubMed ID: 10517727
    [No Abstract]   [Full Text] [Related]  

  • 4. Enoxaparin in acute coronary syndromes: evidence for superiority over placebo or untreated control.
    Massel D; Cruickshank MK
    Am Heart J; 2002 May; 143(5):748-52. PubMed ID: 12040333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials.
    Fox KA
    Am J Cardiol; 1999 Sep; 84(5A):26M-31M. PubMed ID: 10505540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
    Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Xa activity with low-molecular-weight heparin, enoxaparin, during pregnancy in women with mechanical heart valves.
    Izaguirre R; De La Peña A; Ramírez A; Cortina E; Huerta M; Salazar E
    Proc West Pharmacol Soc; 2002; 45():127-8. PubMed ID: 12434554
    [No Abstract]   [Full Text] [Related]  

  • 8. Unfractionated and low-molecular-weight heparins in acute coronary syndromes: current recommendations.
    Brener SJ
    Cleve Clin J Med; 2000 Jan; 67(1):59-65. PubMed ID: 10645678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Low-molecular weight heparin and acute coronary syndrome: theoretical background and its use in clinical practice].
    Ottani F; Ferrini D; Di Pasquale G; Galvani M
    Ital Heart J Suppl; 2001 Sep; 2(9):958-71. PubMed ID: 11675833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spontaneous pectoral hematoma secondary to enoxaparin for the treatment of deep venous thrombosis in an elderly man.
    Ozpolat B; Yazkan R; Aksoy M; Doğan S
    Anadolu Kardiyol Derg; 2008 Dec; 8(6):E40. PubMed ID: 19103532
    [No Abstract]   [Full Text] [Related]  

  • 11. How should we define major bleeding events in thromboprophylaxis?
    Bottaro FJ; Ceresetto JM
    J Bone Joint Surg Am; 2010 Nov; 92(15):2617-8; author reply 2618-9. PubMed ID: 21048185
    [No Abstract]   [Full Text] [Related]  

  • 12. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischemic stroke (Cochrane review).
    Counsell C; Sandercock P
    Stroke; 2002 Jul; 33(7):1925-6. PubMed ID: 12105377
    [No Abstract]   [Full Text] [Related]  

  • 13. Anticoagulants in acute coronary syndromes.
    Turpie AG
    Am J Cardiol; 1999 Sep; 84(5A):2M-6M. PubMed ID: 10505536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enoxaparin in acute coronary syndromes.
    Lee S; Gibson CM
    Expert Rev Cardiovasc Ther; 2007 May; 5(3):387-99. PubMed ID: 17489664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep venous thrombosis: outpatient therapy with low-molecular-weight heparin.
    Tapson VF
    Manag Care; 1999 Dec; 8 Suppl():2-6. PubMed ID: 11729399
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II).
    Ross AM; Molhoek P; Lundergan C; Knudtson M; Draoui Y; Regalado L; Le Louer V; Bigonzi F; Schwartz W; de Jong E; Coyne K;
    Circulation; 2001 Aug; 104(6):648-52. PubMed ID: 11489769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fondaparinux versus enoxaparin in acute coronary syndromes.
    Majure DT; Aberegg SK
    N Engl J Med; 2006 Jun; 354(26):2829; author reply 2830. PubMed ID: 16807423
    [No Abstract]   [Full Text] [Related]  

  • 18. Low molecular weight heparins in acute coronary syndrome.
    Creekmore F
    S D J Med; 2000 Jan; 53(1):21-3. PubMed ID: 10652862
    [No Abstract]   [Full Text] [Related]  

  • 19. Does enoxaparin have enough FINESSE to replace unfractionated heparin in primary percutaneous coronary intervention?
    Goodman SG
    JACC Cardiovasc Interv; 2010 Feb; 3(2):213-4. PubMed ID: 20170879
    [No Abstract]   [Full Text] [Related]  

  • 20. Complications of low-molecular-weight heparin in surgical patients with impaired renal function.
    Hanly EJ; Strobel LM; Mittendorf EA
    Curr Surg; 2005; 62(3):358-61. PubMed ID: 15890228
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.